Complete Lesion Assessment With ffR and IVUS TechnologY

Not Applicable

Completed

• Conditions: Peripheral Artery Disease; Critical Limb Ischemia
• Interventions: Device: Balloon Angioplasty; Device: Orbital Atherectomy System

• Registration Number: NCT01941030
• Lead Sponsor: Abbott Medical Devices

Brief Summary

CLARITY I is a pilot study to identify the clinically appropriate endpoint(s) of a larger, statistically powered pivotal trial for treatment of patients with Critical Limb Ischemia (CLI).

Detailed Description

This prospective, randomized, multi-center, post-market study of approximately 50 subjects randomized 1:1 to Orbital Atherectomy (OA) performed with Cardiovascular Systems, Inc.'s Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA) vs. BA alone for treatment of tibial vessel disease, defined as ≥ 50 % stenosis of the anterior tibial (AT), posterior tibial (PT), tibial peroneal trunk (TPT), or peroneal (PR) arteries by angiography. All subjects will have a corresponding wound being fed by the target vessel which will be assessed during the study. Subjects will be followed to one year.

Study Timeline

• Study Start: 2013-03
• Study First Submitted: 2013-03-11
• Study First Submitted QC: 2013-09-09
• Study First Posted: 2013-09-13
• Primary Completion: 2015-06
• Study Completion: 2015-06
• Results First Submitted: 2019-01-02
• Results First Submitted QC: 2019-01-02
• Results First Posted: 2019-01-24
• Status Verified: 2023-07
• Last Update Submitted: 2023-07-14
• Last Update Posted: 2023-07-18

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

1. Subject's age ≥ 18 years.
2. Subject is an acceptable candidate for percutaneous intervention with the Sponsor's OAS and BA in accordance with their labeled indications and instructions for use.
3. Subject is willing and able to sign an approved informed consent form (ICF).
4. Subject is willing and able to attend follow-up and wound care visits.

General

Exclusion Criteria

1. Subject is pregnant or planning to become pregnant within the study period.
2. Subject is currently participating in an investigational drug or other device study that can clinically interfere with the endpoints of this trial.
3. Subject has a known sensitivity to contrast media and the sensitivity cannot be adequately pre-medicated.
4. Uncontrolled allergy to nitinol, stainless steel, or other stent materials.
5. Subject has known allergy to atherectomy lubricant components such as soybean oil, egg yolk phospholipids, glycerin or sodium hydroxide.
6. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.
7. Subject has been diagnosed with chronic renal failure or has a creatinine level > 2.5, unless on dialysis, prior to the index treatment.
8. Subject has evidence of intracranial or gastrointestinal bleeding within 90 days.
9. Subject has a history of trauma, fracture, major surgery (includes major amputation), or biopsy of a parenchymal organ within past 14 days, or patient has not healed from a previous medical intervention occurring more than 14 days.
10. Subject has a history of stroke or myocardial infarction (MI) within 90 days prior to enrollment in the study.
11. Subject has a planned major surgery (includes major amputation) scheduled within 60 days after treatment of the index limb.
12. Subject has a planned interventional treatment to address stenosis of the contralateral limb scheduled within 60 days after the index treatment.
13. Subject has a planned interventional treatment to address inflow stenosis of the ipsilateral limb scheduled within 60 days after the index treatment.
14. Inflow or bilateral PAD requiring treatment prior to enrollment was not successfully treated, defined as > 50% residual stenosis and/or occurrence of procedural angiographic complications, excluding dissection types A and B.
15. Subject has previously had their other limb treated as part of the study.

Angiographic Inclusion Criteria:

1. Target lesion(s) located in the anterior tibial (AT), posterior tibial (PT), tibial peroneal trunk (TPT) or peroneal (PR) arteries.
2. Target lesion has ≥ 50 % stenosis by angiography.
3. Subject has a corresponding wound being fed by the target vessel.

Angiographic Exclusion Criteria:

1. Target limb does not have any visual flow to the foot confirmed via distal selective angiography.
2. Thrombus is present or suspected in the target treatment vessel.
3. Target lesion is within a bypass graft or near a previously placed stent.
4. The guide wire cannot be passed across the target lesion.
5. Anterograde access of the lesion is not possible.
6. Subject has angiographic evidence of significant dissection at or near the treatment site.
7. Interventional treatment is intended for in-stent restenosis at the peripheral vascular site.
8. Subject's wound(s) involve multiple angiosomes.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Balloon Angioplasty	Balloon Angioplasty	Balloon Angioplasty (BA) alone
Orbital Atherectomy System	Balloon Angioplasty	Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)
Orbital Atherectomy System	Orbital Atherectomy System	Orbital Atherectomy (OA) is performed prior to adjunctive Balloon Angioplasty (BA)

Primary Outcome Measures

Name	Time	Method
Change in Minimum Lumen Area Percent Stenosis as Assessed by IVUS	Pre-intervention, and post-balloon angioplasty	The pre- (Pre-Tx) and post-treatment (Post-Tx) minimum lumen area percent stenosis. A positive value equates to a decrease in lumen area percent stenosis.
Change in Plaque Area as Assessed by IVUS	Pre-intervention, and post-balloon angioplasty	The pre- (Pre-Tx) and post-treatment (Post-Tx) plaque area. A positive value equates to a decrease in plaque area.
Change in Dense Calcium Area as Assessed by IVUS	Pre-intervention, and post-balloon angioplasty	The pre- (Pre-Tx) and post-treatment (Post-Tx) dense calcium area. A positive value equates to a decrease in dense calcium area.
Change in Necrotic Core Area as Assessed by IVUS	Pre-intervention, and post-balloon angioplasty	The pre- (Pre-Tx) and post-treatment (Post-Tx) necrotic core area. A positive value equates to a decrease necrotic core area.
Percentage of Calcium Removal Out of Lumen Gain as Assessed by IVUS	Post-balloon angioplasty	The post-treatment percentage of calcium removal out of lumen gain at the maximum calcium ablation site. A positive value equates to reduction in calcium out of the lumen gain.
Change in Fibrous Plaque Area as Assessed by IVUS	Pre-intervention, and post-balloon angioplasty	The pre- (Pre-Tx) and post-treatment (Post-Tx) fibrous plaque area. A positive value equates to a decrease in fibrous plaque area.
Change in Fibrofatty Plaque Area as Assessed by IVUS	Pre-intervention, and post-balloon angioplasty	The pre- (Pre-Tx) and post-treatment (Post-Tx) fibrofatty plaque area. A positive value equates to a decrease in fibrofatty plaque area.

Secondary Outcome Measures

Name	Time	Method
Fractional Flow Reserve	Post-orbital atherectomy (OA arm only) and post-balloon angioplasty (both arms)	Fractional flow reserve (FFR) will be measured to assess hemodynamic function following each device procedure. During FFR, adenosine will be given through the femoral artery sheath or access catheter in two doses: 600 mcg and 1200 mcg. A higher FFR is presumed to correlate to better flow which may improve wound healing.

Trial Locations

Locations (8)

Mission Research Institute; 🇺🇸 New Braunfels, Texas, United States

Arkansas Heart Clinic; 🇺🇸 Little Rock, Arkansas, United States

Midwest Cardiovascular Research Foundation; 🇺🇸 Davenport, Iowa, United States

Northside Hospital; 🇺🇸 Atlanta, Georgia, United States

St. John Hospital and Medical Center; 🇺🇸 Detroit, Michigan, United States

Holy Name Medical Center; 🇺🇸 Teaneck, New Jersey, United States

Rex Hospital; 🇺🇸 Raleigh, North Carolina, United States

Sentara Vascular Specialists; 🇺🇸 Norfolk, Virginia, United States